Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma

Mohammed, Doaa A.; Khallaf, Salah M.; El-Naggar, Mohamed G.M.; Abdel-Hameed, Muhamad R.; Bakry, Rania

doi:10.21608/resoncol.2021.51503.1127

	Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma
Research in Oncology
Article 6, Volume 17, Issue 1, June 2021, Page 38-41 PDF (119.01 K)
Document Type: Original Article
DOI: 10.21608/resoncol.2021.51503.1127
View on SCiNiTO
Authors
Doaa A. Mohammed¹; Salah M. Khallaf ²; Mohamed G.M. El-Naggar¹; Muhamad R. Abdel-Hameed³; Rania Bakry¹
¹Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
²Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
³Clinical Hematology Unit, Internal Medicine Department Faculty of Medicine, Assiut University, Assiut, Egypt
Abstract
Background: Identification of high-risk patients with multiple myeloma (MM) is important for improving treatment outcomes. Efforts to identify significant prognostic markers are unremitting. Angiogenesis plays an important mechanism in the progression of MM. One of the mediators of this angiogenic process is interleukin-10 (IL-10). Aim: To assess the role of IL-10 as a prognostic marker in MM. Methods: This was a cross-sectional study that included 39 newly diagnosed patients with MM. Serum IL-10 level was measured using Magnetic Luminex® Assay multiplex. The relationship between IL-10 and tumor stage and other known prognostic markers in MM was studied. Results: The median (interquartile range) value of IL-10 was 3 (2.9 – 3.2) pg/mL. Interleukin-10 level differed significantly according to the revised International Staging System stage of MM, being higher in higher stages. The median (interquartile range) IL-10 level was 2.89 (2.79 – 2.95) pg/mL in stage I, 3 (2.9 – 3.1) in stage II and 3.2 (3.1 – 3.66) in stage III (p = 0.0009). In addition, higher IL-10 correlated significantly with lower hemoglobin (p = 0.002), lower albumin (p = 0.045), higher creatinine (p = 0.009), higher β2-microglobulin (p = 0.002), higher lactate dehydrogenase (p = 0.0007) and higher bone marrow plasma cell percentage (p = 0.015). Conclusion: The results support a prognostic role of IL-10 in MM and its pathogenesis.
Keywords
Cytokines; Interleukin−10; Multiple myeloma; Prognosis; Tumor burden


Statistics Article View: 773 PDF Download: 3,265